Figure 4.
Design of MD2-based TLR4 antagonists utilizes the structural similarity of agonists and MD2, which results in competition between antagonists and MD2 for TLR4 binding. For TLR4 binding with antagonists, such as MD2-I, the formation of the MD2-TLR4 complex may be blocked.